Uppsala Reports editor
Real-world data, or observational data collected during routine clinical care, could be a valuable source of evidence in pharmacovigilance. However, there are still hurdles to overcome before it can deliver on that value.
In the latest episode of the Drug Safety Matters podcast, Federica Santoro and Patrick Ryan from Johnson & Johnson discuss the challenges of using real-world data for patient safety and how this resource may be harnessed for pharmacovigilance through some ‘proof of concept’ projects such as OHDSI and EHDEN.
Like what you hear? Then subscribe to the podcast by visiting the Drug Safety Matters website.